


March 24-26 | Boston, MA
www.immune-resetting-summit.com

REGISTER BEFORE
DECEMBER 19 &
SAVE UP TO \$1,000!



Immune Resetting: B-Cell Mediated & Beyond Summit

Accelerating Curative Therapies for Autoimmune Diseases

Pioneering a Transformative Era in Autoimmunity through B-Cell Depletion & Advancing Precision Therapies to Reprogram the Immune System & Move Beyond Standard Immunosuppression

Expert Speakers Include:



Jason Stadanlick
Principal Scientist
Cabaletta Bio



Tom Wickham
Chief Scientific Officer
GentiBio



Chloe Slichter
Director – Discovery Biology
Kite Pharma



Ricardo Grieshaber-Bouyer
Professor – Clinical Systems Immunology
Friedrich-Alexander-Universität Erlangen-Nürnberg



Jeff Jones
Chief Medical Officer
Cullinan Therapeutics



Min Bao
Chief Medical Officer & Co-founder
Kali Therapeutics

“I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule, HB2198, for depletion of CD19/CD20 expressing B-cells.”

Steve Chapin, Senior Director, Hinge Bio

+1 617 455 4188 @ info@hansonwade.com

www.immune-resetting-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Gateway to Collaborate with Pioneers Transforming the Immune Resetting Landscape

 Immune Resetting: B-Cell Mediated & Beyond Summit
March 24-26, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

With the era of blanket immunosuppression coming to an end, a new narrative is emerging where B-cell depletion therapies have taken center stage. But the question remains, what's the next breakthrough?

Cell therapy, T-cell engagers, bispecifics, and more traditional **monoclonal antibody** approaches are creating a huge wave of excitement in autoimmunity, set to **target** and **deplete** immune cells, and **reset the immune system**. What was once blue sky thinking in autoimmunity is now becoming a reality.

In a field rife with investment such as **Kite Pharma's** acquisition of **Interius Biotherapeutics** and **AbbVie's** acquisition of **Capstan**, along with the rising interest in targeting BCMA for lupus nephritis, the landscape of autoimmune treatment is being transformed into this **new era of precision therapies**.

The inaugural **Immune Resetting: B-Cell Mediated & Beyond Summit** arrives at this pivotal point for biopharma, bringing together leaders to share insights, forge connections and accelerate progress towards making immune system resetting a reality for autoimmune patients. From discovery through to clinical application, this is your opportunity to convene with senior decision-makers, academic KOLS, and immunology innovators to benchmark strategies and take actionable lessons back to your programs.

Key themes will include:

-  **Driving deep B-cell depletion** to strike at the root of autoantibody production and immune dysregulation, unlocking the potential for durable, transformative therapies that redefine autoimmune care
-  **Targeting novel pathways** like BCMA to strike at the source of autoantibody production, delivering a deeper, more durable immune reset and reshaping the future of autoimmune therapy
-  **Showcasing cutting-edge approaches** such as CAR T-cell therapies, T-cell engagers, Tregs, bispecifics, and targeted biologics, delivering precision and personalization to reset the immune system
-  **Uncovering the ripple effects of immune resetting** across T-cell and innate compartments, revealing how B-cell modulation can recalibrate the entire immune system, restore self-tolerance, and unlock the blueprint for the next generation of therapies with curative potential

Join **50+ leading autoimmune experts, immunologists, and pioneering companies** to explore how a single, targeted intervention can reprogram the immune system, unlocking long-term, potentially curative therapies for devastating diseases like lupus, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, and beyond.


5 Key Benefits of Attending



Unpack the essence of a 'true immune reset' and tackle the pivotal challenge of optimal depth of depletion, guided by insights from **Kite Pharma** and **Friedrich-Alexander-Universität Erlangen-Nürnberg**



Assess BCMA targeting as a breakthrough approach to eliminate resilient plasma cells that survive CD20/CD19 depletion, with insights from **Ouro Medicines**



Explore cutting edge treatment strategies such as bispecific ADCs, myeloid and NK cell engagers, designed to achieve profound B-cell depletion without the need for lymphodepletion with insights from innovators at **Hinge Bio** and **VelaVigo**



Advance the use of off-the-shelf cell therapies for autoimmunity through the advancement of allogeneic and *in vivo* cell therapy with **Sail Biomedicines** and **Cabaletta Bio**



Expand the immune resetting horizon moving past B-cell targets to myeloid cells, NK cells and controlled T-cell depletion with **Marengo Therapeutics** and **Genti Bio**

What Our Speakers have to Say

“I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.”

Jason Stadanlick,
Principal Scientist,
Cabaletta Bio


“This is a rapidly evolving space, and the collaboration and information shared from companies was incredibly valuable at the TCEs for Autoimmune Disease Summit. I think we all believe we are competing but also each success will help the whole field out.”

Tapan Maniar, Chief
Medical Officer, Oblenio
Bio

What to Expect at the Inaugural Immune Resetting Summit

Immune Resetting: B-Cell Mediated & Beyond Summit
March 24-26, 2026 | Boston, MA

Navigating the Agenda



Key Sessions Not To Miss

Define what true immune resetting really means in the Morning Workshop Session - **Defining Immune Resetting: Translational Approaches to Profiling B-Cells to Understand the Depth of Depletion**. Join **Kite Pharma** and **Ricardo Greishaber-Bouyer** to uncover how deep B-cell depletion must go, the biomarkers that prove it, and the cutting-edge profiling tools shaping the next generation of autoimmune therapies.

Join the debate on the most pressing challenges and breakthrough insights shaping clinical development for B-cell targeted therapies in autoimmune disease. Engage with leaders from **Bristol Myers Squibb** and **Cullinan Therapeutics** as they define patient populations best suited for immune resetting therapies and uncover the critical 'window of opportunity' to intervene in disease progression.

Break beyond B-cell targeting and explore the next frontier in autoimmune remission. Join **Marengo Therapeutics** to uncover why disrupting the T/B-cell axis and precisely modulating pathogenic T-cell subsets is key to achieving durable immune reset.

Unlock the potential of BCMA in autoimmune therapy. Join **Ouro Medicines** to explore how BCMA-targeted approaches enable broad B-cell depletion, eliminate long-lived plasma cells, and weigh the pros and cons versus other B-cell targets.

Connect, collaborate, and showcase innovation at our **Poster Session**. Share your research and explore cutting-edge work spanning drug discovery to clinical breakthroughs, while networking with immune-resetting experts eager for the next big idea.

Companies Attending in 2026



Your 18+ Expert Speakers



Immune Resetting: B-Cell
Mediated & Beyond Summit

March 24-26, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Academic All-Stars



Ricardo Grieshaber-Bouyer
Professor - Clinical
Systems Immunology
**Friedrich-Alexander-
Universität Erlangen-
Nürnberg**



Mark Shlomchik
Distinguished Professor &
UPMC Endowed Chair
University of Pittsburgh

Global Big Pharma Trailblazers



Brandon Law
Director - Clinical
Development
Bristol Myers Squibb



Chloe Slichter
Director - Discovery
Biology
Kite Pharma

Immunology Innovators



Lisa Guerrettaz
Executive Director,
Pharmacology &
Translational Science
Artiva Biotherapeutics



Jason Stadanlick
Principal Scientist
Cabaletta Bio



Irina Shapiro
Vice President -
Translational Research
Cullinan Therapeutics



Jeff Jones
Chief Medical Officer
Cullinan Therapeutics



Tom Wickham
Chief Scientific Officer
GentiBio



Steve Chapin
Senior Director - Preclinical
Development
Hinge Bio



Jinyang Li
Principal Scientist
Innovent Biologics



Min Bao
Chief Medical Officer &
Co-Founder
Kali Therapeutics



Zhen Su
Chief Executive Officer &
Member Board of Directors
Marengo Therapeutics



Tapan Maniar
Chief Medical Officer
Oblenio Bio



Jaideep Dudani
Chief Executive Officer
Ouro Medicines



Christian Furlan Freguia
Senior Vice President –
Research
Rise Therapeutics



Michael Mingueneau
Vice President –
Immunology
Sail Biomedicines



Jing Li
Founder & Chief Executive
Officer
VelaVigo

Pre-Conference Workshop Day

Tuesday, March 24

Check In & Coffee

8.30

Morning Session

9.00

Defining Immune Resetting: Translational Approaches to Profiling B-Cells to Understand the Depth of Depletion

Join this workshop to discuss how we measure the immune reset and to what depth must we deplete B-Cells:

- Clarifying the constitution of a true 'immune reset' following B-cell depletion therapy vs transient immunosuppression
- Discussing the restoration of the stable self-tolerant immune system
- Understanding optimal depletion targets to understand which populations must be depleted and to what extent to achieve a sustainable therapeutic effect
- Reflecting on the necessary therapeutic strategies needed to target long-lived plasma cells within the bone marrow
- Advancing B-cell profiling techniques such as single-cell RNA sequencing, flow, and mass cytometry, and adaptive immune receptor repertoire sequencing
- Discussing the effective definition of B-cell depletion through cellular and molecular biomarkers that correlate with depletion depth and sustained immune reset

Workshop Leaders



Chloe Slichter
Director –
Discovery Biology
Kite Pharma



Ricardo Greishaber-Bouyer
Professor –
Clinical Systems
Immunology
Friedrich-Alexander-Universität Erlangen-Nürnberg

Lunch Break & Networking

12.00

Afternoon Session

1.00

Advancing Diagnostics & Biomarkers to Definitively Characterize the B-Cell Repertoire & Success of Immune Resetting Therapeutics in a Clinical Setting

Join this workshop to explore how immune resetting is being measured in the clinic:

- Highlighting the disconnect between B-cell levels in peripheral blood and their persistence in the lymph nodes following conventional antibody therapies
- Discussing the necessity of lymph node biopsies as a direct, *ex vivo* method to accurately quantify the depth of depletion to address the disruption of the follicular pathway in the lymph nodes to provide a measure of therapeutic effects
- Comparing the tissue outcomes across different therapeutic modalities linking deep lymphoid tissue depletion to the potential for sustained, long-term remission
- Effectively analyzing the B-cell repertoire to gain insights into effectiveness of the treatment after resetting the immune system
- Utilizing B-cell receptor gene sequencing to precisely track and confirm the deep and sustained elimination of these initial pathogenic B-cells following immune-resetting therapy
- Ensuring newly generated B-cells are free of the original pathogenic B-cells as molecular evidence for the restoration of self-tolerance
- Establishing molecular signatures that predict long-term remission

Workshop Leaders



Irina Shapiro
Vice President -
Translational
Research
Cullinan Therapeutics

End of Pre-Conference Workshop Day

4.00

Conference Day One

Wednesday, March 25



8.00 Check In & Coffee

8.50 Chair's Opening Remarks

Evaluating & Defining the 'Immune Resetting' Landscape in a New Era of Curative Therapies for Autoimmune Diseases



Mark Shlomchik
Distinguished Professor
& UPMC Endowed
Chair
**University of
Pittsburgh**

9.00 **From Suppression to Resetting: Outlining a New Era in an Evolving Therapeutic Landscape for Autoimmunity**

- Identifying the clinical and molecular criteria that differentiate a true 'immune reset' from traditional immune suppression techniques
- Understanding the current landscape of modalities achieving deep depletion of pathogenic immune memory cells necessary for immune rebooting
- Diving into the current hurdles to making immune resetting therapies a standard of care such as manufacturing scalability, off-target effects, safety and developing biomarkers



Chloe Slichter
Director – Discovery
Kite Therapeutics



9.30 **CAR T-Cell Combination Approaches for Complete Immune Reset**

- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing base editing to enable CAR T-cell combination therapies for B-cell targeting and beyond
- Discussing the possibility of B-cell reconstitution, focusing on whether the new B-cell compartment is "reset" to a non-autoreactive state

10.00 **Panel Discussion: Walking the Therapeutic Tightrope Between Efficacy & Safety in B-Cell Targeted Therapies for Autoimmune Diseases vs Oncology**

CLINICAL

Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:

- Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
- Addressing the risks associated at various level of depletion such as elevated BAFF
- Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion



Chloe Slichter
Director – Discovery
Kite Therapeutics



Min Bao
Chief Medical Officer
Kali Therapeutics



Ricardo Greishaber-Bouyer
Professor – Clinical Systems
Immunology
**Friedrich-Alexander-Universität
Erlangen-Nürnberg**



10.30 **Speed Networking**

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the immune resetting field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.



11.15 **Morning Refreshments & Networking**

Conference Day One

Wednesday, March 25

Exploring Next-Generation Therapeutic Modalities to Bring Curative Therapies for Larger Patient Populations



Min Bao
Chief Medical Officer
Kali Therapeutics

11.30 Defining the Target, Dose, & Indication for Complete Immune Reset Beyond CD20

TCE

- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing available clinical data to inform target selection and match T-cell engager targets to the correct autoimmune indication
- Exploring the dosing challenges for high-efficacy T-cell engagers and determining whether intermittent high doses or continuous lower doses are optimal to balance efficacy and safety



Tapan Maniar
Chief Medical Officer
Oblenio Bio

12.00 Leveraging Bi- & Tri-Specific Antibodies for a Deep & Targeted Immune Reset

TCE

CLINICAL

- Understanding the mechanism of action for bi- and tri-specific antibodies enhancing cytotoxicity and phagocytosis through forced proximity for B-cell depletion
- Exploring how multi-specificity can overcome therapeutic resistance by targeting multiple antigens across the B-cell lineage
- Managing CRS risk for CD3 engagement in non-oncology populations in non-IgG-like multi-specific antibody constructs

Successfully Matching Modalities to the Disease Driver for Specific & Targeted Therapies



12.30 Lunch & Networking



Jinyang Li
Principal Scientist
Innovent Biologics

1.30 Development & Characterization of IBI3055, a 2+1 Format, CD19 & BCMA Dual Targeting T-Cell Engager for Autoimmune Diseases

TCE

- Novel T-cell engager for autoimmune diseases
- CD19 and BCMA targeting therapies for B-cell and plasma cell depletion
- New therapeutic approaches for drug for immune resetting



Chloe Slichter
Director – Discovery
Biology
Kite Pharma

2.00 Roundtable Discussion: Diving Deep into the Modality Matrix to Determine the Optimal Approach for Immune Resetting

COMBINATION
THERAPY

- Matching the modality to the pathogenic cell subset driving the disease
- Comparing the logistical and risk profiles of different classes of therapies and defining an acceptable risk-benefit ratio for large autoimmune patient populations
- Exploring the potential for combination therapies pairing a single dose reset agent with a subsequent maintenance modality to enhance durability and reduce relapse risk



2.30 Afternoon Refreshments & Poster Sessions

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the immune resetting world. Don't miss out on the chance to submit your own posters and get ready to connect, learn, and present.

To submit your poster please contact info@hansonwade.com

Conference Day One

Wednesday, March 25

Unpacking the Latest Challenges & Insights in Clinical Development for B-Cell Targeted Therapies for Autoimmune Diseases



Brandon Law
Director – Clinical Development
Bristol Myers Squibb

3.30

Tackling Immune Resetting in Multiple Sclerosis Through Translating CNS-Targeted B-Cell Depletion into Long-Term Remission

CLINICAL

- Understanding the therapeutic promise of CAR-T through its ability to cross the blood-brain barrier to achieve immune reset by eliminating the CNS-resident B-cells driving progressive MS pathology
- Leveraging the immune-resetting potential through early intervention to prevent the accumulation of permanent disability rather than treating symptoms of a late-stage progressive disease
- Establishing the clinical trial endpoints and regulatory frameworks necessary to prove the durable, long-term benefit and commercial viability of single-dose, curative therapies in a diverse patient population



Ricardo Greishaber-Bouyer
Professor – Clinical Systems Immunology
Friedrich-Alexander-Universität Erlangen-Nürnberg

4.00

Fireside Chat: Effectively Operationalizing Clinical Trials in Immune Resetting Therapeutics

CLINICAL

- Securing Centre's of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
- Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
- Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible



Jeffrey Jones
Chief Medical Officer
Cullinan Therapeutics

4.30 Panel Discussion: Defining Patient Populations for B-Cell Depletion Therapies & Establishing a 'Window of Opportunity' for Treatment

CLINICAL

- Determining the optimal time to deploy B-cell depletion, focusing on using 'immune reset' therapies early in the course of the disease development
- Comparing the efficacy of standard peripheral B-cell depletion against next-generation therapies designed to achieve a complete, deep-depletion
- Defining new clinical endpoints and securing regulatory approval for a curative-intent treatment that aims to halt disease progression early across a broad, heterogeneous autoimmune patient population



Brandon Law
Director – Clinical Development
Bristol Myers Squibb



Tapan Maniar
Chief Medical Officer
Oblenio Bio



Jeff Jones
Chief Medical Officer
Cullinan Therapeutics

5.00 Chair's Closing Remarks

5.10 End of Conference Day One

Conference Day Two

Thursday, March 26



8.30 Check In & Coffee

8.50 Chair's Opening Remarks

Tackling the Safety-Durability Equation in B-Cell Depletion by Mitigating Risks & Maximizing Drug-Free Remission



Jing Li
Chief Executive Officer
& Founder
VelaVigo

9.00

The Trispecific TCE or Bispecific ADC: A New Way to Deeply Deplete B-Cells Potentially for Oncology & Autoimmune Diseases

TCE

COMBINATION
THERAPY

- Examine the potential of trispecific T-cell engagers TCEs and bispecific ADCs as next-generation strategies for deep B-cell depletion across oncology and autoimmune indications
- Understand the mechanistic advantages of multi-specific modalities in enhancing precision, potency, and durability compared to traditional approaches
- Explore translational insights and early data shaping the clinical promise of these innovative platforms for redefining treatment paradigms



Lisa Guerrettaz
Executive Director,
Pharmacology &
Translational Science
Artiva Bio

9.30

From CAR-T Complexity to NK Cell Simplicity: Artiva Biotherapeutics' Allogeneic NK cells Plus Anti-CD20 Monoclonal Antibodies Drive Consistent B-Cell Depletion

CELL
THERAPY

CLINICAL

- Highlight the scientific rationale and potential benefits of combining non-genetically modified NK cell therapy with monoclonal antibodies for treating autoimmune diseases
- Provide an overview of the translational strategy and underlying principles
- Review clinical evidence showing that NK cell therapies can achieve deep and consistent B-cell depletion in autoimmune diseases while minimizing adverse effects commonly associated with CAR-T and TCE approaches
- Review indication selection in RA given tolerability, accessibility, and ease of use in community setting



10.00 Morning Refreshments & Networking

Next-Generation Cell Therapies for Immune Resetting from Autologous Isolation to Off-the-Shelf Allogeneic Solutions

10.30

Exploring Autologous CD-19 CAR-Ts for Rheumatology to Advance Treatment Development for Orphan Diseases

CELL
THERAPY



Jason Standanlick
Principal Scientist
Cabaletta Bio

- Discussing the emerging clinical data showing deep, sustained B-cell depletion in Lupus patients
- Exploring whether depth of depletion translates into long-term, drug-free remission that has been unattainable with conventional treatments
- Identifying signatures in the repopulating B-cell and T-cell compartments that predict durable remission and guide the regulatory pathway for a curative therapy

11.00 Panel Discussion: Making Cell Therapy for Autoimmunity an Off-the-Shelf Treatment Through the Advancement of Allogeneic & *In Vivo* Cell Therapies

CLINICAL

CELL
THERAPY

Join this session for a candid conversation with experts pursuing the reality of off-the-shelf cell therapies:

- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy



Jason Standanlick
Principal Scientist
Cabaletta Bio



Tom Wickham
Chief Scientific Officer
GentiBio



Chloe Slichter
Director - Discovery
Biology
Kite Pharma

Conference Day Two

Thursday, March 26

Uncovering the Next Frontier in Immune Resetting Beyond B-Cell Mediated Therapies



Jaideep Dudan
Chief Executive Officer
Ouro Medicines

11.30

Unraveling the Role of the BCMA in B-Cell Depletion for Autoimmunity

- Highlighting the ability of BCMA T-cell engagers to induce the broad depletion of peripheral and tissue B-cells
- Analyzing the utility of BCMA targeting as a modality to eliminate long-lived plasma cells which can survive CD20 and CD19 depletion
- Discuss the pros and cons of targeting BCMA vs other B-cell targets

TCE



12.00

Lunch & Networking



Zhen Su
Chief Executive Officer & Member
Board of Directors
Marengo Therapeutics

1.00

Pursuing T-Cell Targeting for the Next Frontier in Autoimmune Remission

- Discussing why B-cell targeted therapies alone is often insufficient
- Emphasizing the need to break the T/B-cell axis to modulate T-helper cells that provide survival and differentiation signals for pathogenic B-cells
- Defining the necessary therapeutic precision, selective manipulation or depletion of pathogenic T-cell subsets while preserving the protective, conventional T-cell immunity

BEYOND
B-CELL



Christian Furlan Freguia
Senior Vice President -
Research
Rise Therapeutics

1.30

Training Dendritic Cells Through Oral Therapy to Restore Immune Balance

- Developing orally delivered immune biomodulators that selectively reprogram dendritic cells within the gut mucosa to drive systemic immune resetting
- Demonstrating how targeted conditioning of intestinal dendritic cells induces tolerogenic pathways, restores regulatory T-cell activity, and exerts downstream control of B-cell hyperactivation
- Summarizing key preclinical and emerging clinical findings, discuss platform design principles, and outline how oral immune therapies can provide safer, more durable, and more accessible treatment options for autoimmune and inflammatory diseases

BEYOND
B-CELL



Steve Chapin
Senior Director
– Preclinical
Development
Hinge Bio

2.00

HB2198 GEM-DIMER™: A Novel Myeloid & NK Cell Engager for Deep Depletion of B-Cells

- HB2198 is an anti-CD19/CD20 bispecific antibody with dual enhanced Fc domains created with Hinge Bio's GEM-DIMER™ technology
- HB2198 exhibits potent B-cell depletion *in vitro*, demonstrating ADCC, ADCP, CDC and direct killing
- HB2198 rapidly depletes B-cells and results in durable remodeling of the B-cell compartment in cynomolgus monkeys with no cytokine release up to 25 mg/kg. Preparations for Phase 1 clinical trial in SLE/LN ongoing

BEYOND
B-CELL



Michael Mingueneau
Vice President –
Immunology
Sail Biomedicines

2.30

In Vivo Transient Programming of T Cells with Targeted Nanoparticles Encapsulating eRNA-encoded hCD19 CAR Achieves Deep Depletion of B cells in tissues and immune Reset

- In vivo CAR-T cell engineering has the potential to transform the care of patients with autoimmune diseases by simplifying and broadening access to treatments with potential for cures
- Sail's in vivo CAR-T drug candidate (DC) has been engineered and extensively optimized to achieve an optimal dose efficiency profile and ultimately therapeutic index in patients with autoimmune conditions. As a result, Sail's in vivo CAR-T DC is able to achieve deep tissue depletion of B cells and effectively reset the B cell compartment at low dose levels
- Sail's in vivo CAR-T DC has the potential to replace complex, costly, and genome-integrative cell therapy products with an off-the-shelf and non-integrative IV injectable product that avoids the safety risks associated with lymphoablative conditioning

3.30

Chair's Closing Remarks

3.40

End of Conference

Take the Spotlight & Partner with the Immune Resetting: B-Cell Mediated & Beyond Summit



Immune Resetting: B-Cell Mediated & Beyond Summit

March 24-26, 2026 | Boston, MA

Your Global Platform to Foster New & Existing Relationships within the Rapidly Evolving Immune Resetting Field

The **Immune Resetting: B-Cell Mediated & Beyond Summit** is the premier industry event dedicated to accelerating curative therapies for autoimmune diseases. This unique meeting brings together leading biopharma innovators to define immune resetting, assess the depth of B-cell depletion, and uncover the downstream effects on T-cell and innate immune compartments, driving the next wave of transformative breakthroughs.

For the first time, C-level executives, VPs, directors, and leading academics will unite with a singular focus: **unlocking the next wave of breakthroughs in immune resetting for B-cell mediated autoimmune diseases and beyond**. This is your moment to showcase expertise and influence industry pioneers across every stage of drug development and autoimmune indications.

Our audience of decision makers are looking to partner with expert service providers offering:

Advanced Genomic & Cell Sequencing Technologies

Specialist Autoimmune Models

CROs specializing in advanced autoimmune trials

Partnering with the **Immune Resetting: B-Cell Mediated & Beyond Summit** gives you an unrivaled platform to:



Position your organization at the cutting edge of novel modality development, from *in vivo* CAR-T and TCEs to next-generation monoclonal antibodies, bi- and trispecific antibodies, and ADCs for B-cell depletion and immune resetting



Showcase technical leadership in advanced cell sequencing technologies to precisely characterize B- and T-cell dynamics throughout the immune resetting process



Develop strategic collaborations with top innovators by presenting preclinical models that enhance translatability for B-cell mediated autoimmune diseases and beyond



Engage directly with key decision-makers to establish CRO partnerships early in drug development and secure long-term business opportunities

Elevating Your Presence

EXHIBITION BOOTH

SPEAKING POSITION


PRIVATE LUNCHES

DRINKS RECEPTION


SEAT DROP

With 'immune resetting' emerging as one of the most transformative concepts in drug development, this is your gateway to accelerating industry-wide innovation, shaping the competitive landscape, and forging long-term partnerships that will drive the next wave of approvals.

Seniority of Attendees



Type of Companies Attending



*Statistics taken from the inaugural T-Cell Engager for Autoimmune Disease Summit in October 2025

Get Involved



Nicolas Ramovic
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.immune-resetting-summit.com

 Tel: +1 (617) 455 4188

 Email: info@hansonwade.com



Uncover cutting-edge technologies that define what a true 'immune reset' really means distinguishing lasting B-cell depletion from transient immunosuppression



Assess how diverse therapeutic modalities can be strategically deployed to target multiple indications, minimize toxicity, and extend the durability of B-cell depletion therapies



Gain forward-looking insights into emerging immune-resetting targets T-cells, NK cells, and myeloid cells to inform next-generation combination strategies that enhance safety and long-term efficacy

Drug Developers	Register & Pay By Friday, December 19	On the Door Price
Conference + Workshop Day	\$3,397 (Save \$1,000)	\$4,397
Conference Only	\$2,599 (Save \$500)	\$3,099

Academic & Small Biotechs**	Register & Pay By Friday, December 19	On the Door Price
Conference + Workshop Day	\$2,797 (Save \$1,000)	\$3,797
Conference Only	\$2,199 (Save \$500)	\$2,699

Solution & Service Providers	Register & Pay By Friday, December 19	On the Door Price
Conference + Workshop Day	\$4,297 (Save \$1,000)	\$5,297
Conference Only	\$3,299 (Save \$500)	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & small biotech rate you must be full time academic or be part of a biotech that is <2 years old or has <30 employees and does not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

AKA Back Bay, 154 Berkely Street, Boston, MA

02116, United States

<https://www.stayaka.com/hotel-aka-backbay>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom